View larger version (47K):
[in this window]
[in a new window]
|
FIGURE 5. (A) Coronal images of C57 mice implanted with B16/F1 tumors at 30 min and at 2, 4, and 24 h after tail vein injection of 5.55 MBq (150 µCi) (500 ng) of 64Cu-CBTE2A-ReCCMSH(Arg11). At each time point a mouse that received blockade (left) was coimaged with a mouse that did not receive blockade (right). Blockade mouse received 20 µg of CBTE2A-ReCCMSH(Arg11). Images shown are 1-mm slices, with animal in supine position, and slices shown are through center of tumor volume. As tumors do not grow in exactly the same location from animal to animal, slices may show different tissues in addition to tumors. PET images show that administration of a blockade dose substantially reduces tumor uptake of the agent by such an extent that tumor is difficult to delineate. It is also evident that background accumulation is very low, resulting in excellent tumor contrast. T = tumor; K = kidney. (B) microPET/CT coregistered images of B16/F1 tumor-bearing mice 2 h after tail vein injection of 5.5 MBq (500 ng) of 64Cu-CBTE2A-ReCCMSH(Arg11). Images shown are 1-mm slices and slices shown are through center of tumor volume.
|
-MSH Peptide Analog Using a Cross-Bridged Cyclam Chelator
) (8) and 64Cu-CBTE2A-ReCCMSH(Arg11) (185 kBq [5 µCi], 16 ng, n = 5; 
) in B16/F1 tumor-bearing C57 mice at 2 h after injection. Data are presented as %ID/g ± SD. Note differences in y-axis scales.
